Merck's Keytruda Qlex Approved In Japan For Subcutaneous Administration For All Keytruda Indications Approved In Japan
MRK•Japan approval for Keytruda Qlex
Sept. 21 (Reuters) - Merck & Co Inc MRK.N:
- Merck’s Keytruda Qlex™ (pembrolizumab and berahyaluronidase alfa-pmph) approved in Japan for subcutaneous administration for all Keytruda® (pembrolizumab) indications approved in Japan
Source text: ID:nBw49rmXLa
Further company coverage: MRK.N
